On 12 Nov 2026 IQVIA closed at $271.11, +20.3% this year; market cap $45.28bn, P/E 32.5.
Health Care · Life Sciences Tools & Services · NYSE · United States
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
| Market cap | $45.28bn |
| P/E (trailing) | 32.5 |
| EPS (TTM) | $8.35 |
| Beta | 1.17 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 27 Oct 2026 |
| Next earnings | 24 Jan 2027 |
| YTD | +20.3% |
| 1Y | +22.7% |
| 3Y | +11.9% |
| 5Y | +1.3% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $16.31bn | $1.36bn | $2.05bn |
| 2024 | $15.40bn | $1.37bn | $2.11bn |
| 2023 | $14.98bn | $1.36bn | $1.50bn |
| 2022 | $14.41bn | $1.09bn | $1.59bn |
| 2021 | $13.87bn | $966.00m | $2.30bn |
We publish no single base value for IQVIA. Our valuation methods put it between $214.38 and $237.80 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.